Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 26;40(5):192.
doi: 10.1007/s11011-025-01619-5.

Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy

Affiliations
Review

Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy

Anibh Martin Das. Metab Brain Dis. .

Abstract

Hyperammonaemia is an important cause for encephalopathy. Ammonia is the waste product of amino acid degradation and cannot be excreted via urine. Ammonia is metabolized to water-soluble urea via the urea cycle. Hyperammonaemia not only occurs during acute liver failure, but also in rare genetically determined defects of enzymes or transporters involved in the urea cycle resulting in elevated ammonia concentrations. Enzyme defects include deficiency of carbamylphosphate synthase, N-acetylglutamate synthase, ornithine transcarbamylase, argininosuccinate lyase and arginase, transporter defects are citrin deficiency and HHH-syndrome. These urea cycle defects (UCD) mostly manifest for the first time during the neonatal period, infancy or childhood, however first clinical manifestations including encephalopathy may be observed in adulthood in milder forms. Therefore, physicians treating adults should be aware of clinical symptoms in UCD to make a timely diagnosis and initiate treatment. In adulthood, clinical symptoms are often uncharacteristic including headache, avoidance of high-protein food, psychiatric symptoms triggered by heavy exercise or delivery of a child, autism, attention deficit, lethargy, developmental delay and epilepsy. Elevated ammonia concentrations in blood are the biochemical hallmark. Some UCDs can be diagnosed at metabolite level, others only at genetic level. Treatment consists of eucaloric, low-protein diet supplemented with essential amino acids and vitamins/trace elements, and intake of arginine or citrulline. Pharmacological scavengers of nitrogen are benzoate and butyrate. If conservative therapy fails, hemodialysis should be considered. Prompt treatment during acute crises is essential for optimal outcome. Liver transplantation is considered in metabolically unstable patients. For arginase deficiency, enzyme replacement therapy is available.

Keywords: Amino acids; Ammonia; Benzoate; Glycerophenylbutyrate; Scavengers; Urea cycle defect.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematic view of the urea cycle. Enzymes, transporters and metabolites involved in the urea cycle. Ammonia resulting from protein degradation is converted to urea. As an example of a UCD, enzyme deficiency of ASS in ASSD is marked by the red bar
Fig. 2
Fig. 2
Schematic view of nitrogen scavengers. The mode of action of the nitrogen scavengers phenylbutyrate (left) and benzoate (right). Both compounds are conjugated with amino acids containing nitrogen atoms (circles) and form water-soluble compounds, which can be excreted via urine

Similar articles

References

    1. Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML (2003 Apr 29 [updated 2017 Jun 22]) Urea cycle disorders overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds). GeneReviews® [Internet]. University of Washington, Seattle, Seattle, pp 1993–2024
    1. Ah Mew N, McCarter R, Izem R, Markus A, Gerstein M, Rice K, Sanz J, Le Mons C, Bartos J, Tuchman M (2020) Comparing treatment options for urea cycle disorders [Internet]. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI) - PubMed
    1. Aires CC, van Cruchten A, Ijlst L, de Almeida IT, Duran M, Wanders RJ, Silva MF (2011) New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 55(2):426–434. 10.1016/j.jhep.2010.11.031 - PubMed
    1. Amayreh W, Meyer U, Das AM (2014) Treatment of arginase deficiency revisited: guanidinoacetate as a therapeutic target and biomarker for therapeutic monitoring. Dev Med Child Neurol 56(10):1021–1024. 10.1111/dmcn.12488 - PubMed
    1. Baruteau J, Jameson E, Morris AA, Chakrapani A, Santra S, Vijay S, Kocadag H, Beesley CE, Grunewald S, Murphy E, Cleary M, Mundy H, Abulhoul L, Broomfield A, Lachmann R, Rahman Y, Robinson PH, MacPherson L, Foster K, Chong WK, Ridout DA, Bounford KM, Waddington SN, Mills PB, Gissen P, Davison JE (2017) Expanding the phenotype in argininosuccinic aciduria: need for new therapies. J Inherit Metab Dis 40(3):357–368. 10.1007/s10545-017-0022-x - PMC - PubMed

MeSH terms

LinkOut - more resources